GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination

Abstract

Our data suggest that the apparent beneficial effects of 20 microg alum-formulated recombinant human GAD65 is not explained by changes in the GAD65Ab epitope pattern.

Inverse vaccination with islet autoantigens to halt progression of autoimmune diabetes

“…Furthermore, no differences were observed in regulatory and proinflammatory serum cytokine levels from baseline in any of the groups [Agardh et al, 2005]. Apparent preservation of b-cell function in the 20-mg Diamyd group was not the result of shifting GAD65 epitope recognition by GADAs [Bekris et al, 2007]. A 5-year follow-up report has been published on the initial 47 LADA patients receiving placebo or Diamyd injections to establish whether the treatment had long-term effects on b-cell function.…”

Prevention Opportunities of Type 1 Diabetes in Children

“…Clinical trials in late-onset autoimmune diabetes in adults (LADA) and adolescents with newly diagnosed type 1 diabetes [21,22] have suggested benefit.…”

Immunotherapy for the Prevention and Treatment of Type 1 Diabetes

“…In the past couple of years, perhaps the most exciting development in the area of tolerance induction has been apparent efficacy of Diamyd vaccine based on the whole recombinant human GAD 65 (rhGAD 65 ) molecule suspended in alum. Clinical trials in late-onset autoimmune diabetes in adults (LADA) (43,44) and adolescents with newly diagnosed type 1 diabetes (45) have suggested benefit. In the latter study, patients receiving just two subcutaneous injections of the vaccine experienced a decline in stimulated C-peptide secretion approximately one-half that in the placebo group.…”